<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0064</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Polymorphisms of <italic>FCRL3</italic> in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Peizeng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Shengping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Liping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hongyan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kijlstra</surname><given-names>Aize</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label>The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China</aff><aff id="aff2"><label>2</label>Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China</aff><aff id="aff3"><label>3</label>Eye Research Institute Maastricht, Department of Ophthalmology, University Hospital Maastricht, Maastricht, the Netherlands</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Professor Peizeng Yang, the First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China, 400016; Phone/FAX: 00862389012851; email:<email xlink:href="peizengy@126.com">peizengy@126.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>11</day><month>5</month><year>2009</year></pub-date><volume>15</volume><fpage>955</fpage><lpage>961</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2009</year></date></history><permissions><copyright-year>2009</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>The polymorphisms of the Fc receptor-like 3 gene (<italic>FCRL3</italic>), a novel immunoregulatory gene, have been shown to be associated with certain autoimmune diseases. This study was designed to examine whether the polymorphisms of <italic>FCRL3</italic> are associated with susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Chinese population.</p></sec><sec sec-type="methods"><title>Methods</title><p>A case-control study was performed in 230 Chinese VKH patients and 301 healthy controls. Four single nucleotide polymorphisms (SNPs; &#x02212;169C/T, &#x02212;110A/G, +358C/G, and +1381A/G) in <italic>FCRL3</italic> were detected using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). human leukocyte antigen -DR4 (<italic>HLA-DR4</italic>) and <italic>HLA-DRw53</italic> genotyping was performed using PCR techniques.</p></sec><sec><title>Results</title><p>The results showed that the frequency of haplotype CACG was significantly lower in patients when compared with that in controls (p=0.0018, corrected p [pc]=0.0288). A significantly higher frequency was found for haplotype CGGG in <italic>HLA-DR4</italic> negative patients than in <italic>HLA-DR4</italic> negative controls (p=9.94&#x000d7;10<sup>&#x02212;8</sup>, Pc=1.59&#x000d7;10<sup>&#x02212;6</sup>). There were no significant differences in the allele and genotype frequencies of the four investigated SNPs between VKH patients and controls. <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> were significantly associated with VKH syndrome (p=3.21&#x000d7;10<sup>&#x02212;16</sup> and p=7.08&#x000d7;10<sup>&#x02212;5</sup>, respectively). Stratification analysis according to <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> did not show any association of <italic>FCRL3</italic> polymorphisms with VKH syndrome.</p></sec><sec><title>Conclusions</title><p>Our study confirms the previous association of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> with VKH syndrome but fails to demonstrate an association between <italic>FCRL3</italic> polymorphisms and VKH syndrome. Haplotype CACG might be a protective haplotype for VKH syndrome, and haplotype CGGG may be a risk haplotype in <italic>HLA-DR4</italic> negative individuals.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Yang</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Vogt-Koyanagi-Harada (VKH) syndrome is one of the most common uveitis entities in China [<xref ref-type="bibr" rid="r1">1</xref>]. The major clinical manifestations of VKH syndrome include panuveitis, pleocytosis in the cerebrospinal fluid, dysacusis, alopecia, poliosis, and vitiligo [<xref ref-type="bibr" rid="r2">2</xref>-<xref ref-type="bibr" rid="r4">4</xref>]. Although the pathogenesis of VKH syndrome remains uncertain, accumulating evidence suggests that both autoimmune and genetic factors are involved in the development of this disease. Previous research showed that VKH is a T-cell-mediated autoimmune disorder predominantly against melanocytes [<xref ref-type="bibr" rid="r5">5</xref>] and that the tyrosinase family proteins may play an important role in VKH disease. Lymphocytes of VKH patients were shown to proliferate in response to tyrosinase or tyrosinase related protein [<xref ref-type="bibr" rid="r6">6</xref>]. VKH occurs most commonly in colored people such as certain Asian, American-Indian, and Spanish populations [<xref ref-type="bibr" rid="r7">7</xref>], particularly in those carrying the genes coding for the human leukocyte antigen (<italic>HLA</italic>), <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> [<xref ref-type="bibr" rid="r8">8</xref>-<xref ref-type="bibr" rid="r10">10</xref>]. A study in our laboratory recently reported that the frequencies of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> were both significantly increased in VKH patients (odds ratios [OR]=13.74 and OR=4.13, p=3.21&#x000d7;10<sup>&#x02013;16</sup> and p=7.08&#x000d7;10<sup>&#x02013;5</sup>, respectively) [<xref ref-type="bibr" rid="r11">11</xref>]. However, the association between VKH syndrome and the <italic>HLA</italic> system does not completely explain the genetic risk for this disease. Investigation of non-<italic>HLA</italic> susceptibility genes for VKH has been an ongoing research subject during recent years [<xref ref-type="bibr" rid="r12">12</xref>].</p><p>Fc receptor-like genes (<italic>FCRL</italic>s), also known as <italic>FCRH</italic>s (Fc receptor homology), cluster in the midst of the classical Fc receptor genes in the human chromosome 1q21&#x02013;23 region [<xref ref-type="bibr" rid="r13">13</xref>]. <italic>FCRL</italic>s with similarity in structure and sequence to the classical <italic>Fc&#x003b3;</italic> receptor genes (<italic>Fc&#x003b3;R</italic>) contain six immunoglobulin (Ig) superfamily members known as <italic>FCRL1</italic>&#x02013;<italic>FCLR6</italic> according to their chromosomal order [<xref ref-type="bibr" rid="r14">14</xref>]. <italic>FCRL3</italic> is predominantly expressed in lymphoid organs, more precisely in germinal centers, and has been linked to the maturation of B cells [<xref ref-type="bibr" rid="r15">15</xref>]. <italic>FCRL3</italic> may play a role in the differentiation of B cells into autoreactive cells and has been presumed to function through modulating signal transduction via activation/inactivation of signaling tyrosine protein kinases [<xref ref-type="bibr" rid="r16">16</xref>]. Recently, polymorphisms of <italic>FCRL3</italic> have been reported to be associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) [<xref ref-type="bibr" rid="r17">17</xref>], Behcet&#x02019;s disease [<xref ref-type="bibr" rid="r18">18</xref>], autoimmune thyroid disease (AITD) [<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r19">19</xref>], and multiple sclerosis (MS) [<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>]. The first two have a strong autoantibody component whereas the latter three are predominately mediated by T-cell response. As an autoimmune disease, VKH may share a common pathogenesis with these autoimmune diseases. Therefore, <italic>FCRL3</italic> was chosen as a target gene for VKH syndrome. Whether SNPs of <italic>FCRL3</italic> are also associated with the susceptibility to VKH syndrome is not yet known, and this question was therefore the subject of the study described here.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study participants</title><p>Patients and controls consisted of 230 Chinese VKH patients and 301 healthy controls. All control subjects were matched ethnically and geographically with the patients. The test subjects were recruited from the Zhongshan Ophthalmic Center of Sun Yat-sen University (Guangzhou, China) and the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). To exclude the immunogenetic backgrounds of different populations, we strictly chose the cases from Chinese Han descendents.</p><p>The diagnosis of VKH syndrome followed the revised criteria for this disease [<xref ref-type="bibr" rid="r22">22</xref>]. The clinical characteristics of the patients are presented in <xref ref-type="table" rid="t1">Table 1</xref>. All subjects gave their written informed consent for this study, and the study protocol was approved by the local institutional ethics committee.</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title><italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> distribution and clinical characteristics of 230 patients with VKH syndrome.</title></caption><table frame="hsides" rules="groups"><col width="97" span="1"/><col width="94" span="1"/><col width="94" span="1"/><col width="96" span="1"/><col width="95" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><bold>Characteristics</bold></th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1"><bold>VKH Patients</bold><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1"><bold><italic>HLA-DR4</italic>+ n=178 (77.4%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DR4</italic>&#x02013; n=52 (22.6%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53</italic>+ n=202 (87.9%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw5</italic>&#x02013; n=28 (12.1%)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">103 (80.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (19.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116 (90.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (9.4%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">75 (73.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27 (26.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">86 (84.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (15.7%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Neck stiffness<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">74 (72.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (27.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">89 (87.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (12.7%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Alopecia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26 (72.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (27.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30 (83.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (16.7%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Poliosis<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65 (73.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (26.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78 (88.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (11.4%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vitiligo<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">41 (74.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (25.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (87.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 (12.7%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dysacusia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57 (69.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (30.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">70 (85.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (14.6%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tinnitus<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">61 (84.7%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (15.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (93.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (6.9%)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Scalp hypersensitivity</td><td valign="top" align="center" rowspan="1" colspan="1">32 (74.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (25.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (88.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (11.6%)</td></tr></tbody></table></table-wrap></sec><sec><title>Single nucleotide polymorphisms and genotyping</title><p>Genomic DNA samples of VKH patients and healthy controls were extracted and isolated from ethylene diamine tetraacetic acid (EDTA)-anticoagulated peripheral blood mononuclear cells (PBMCs) by a conventional salting out method and stored at &#x02212;70&#x000a0;&#x000b0;C until use.</p><p>The four single nucleotide polymorphisms (SNPs) in <italic>FCRL3</italic>, &#x02212;169C/T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7528684">rs7528684</ext-link> or fcrl3_3), &#x02212;110G/A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11264799">rs11264799</ext-link> or fcrl3_4), +358C/G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=945635">rs945635</ext-link> or fcrl3_5), and +1381A/G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761959">rs3761959</ext-link> or fcrl3_6), were genotyped by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Genotyping of the &#x02212;110G/A SNP was performed according to the method described previously [<xref ref-type="bibr" rid="r23">23</xref>]. The primers of the three remaining loci were designed using premier 5.0 software (Premier Biosoft International, Palo Alto, CA). The details of the primers and enzymes used for PCR-RFLP genotyping are presented in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Details of the primers, enzymes, and temperature used in PCR-RFLP genotyping.</title></caption><table frame="hsides" rules="groups"><col width="103" span="1"/><col width="72" span="1"/><col width="106" span="1"/><col width="105" span="1"/><col width="54" span="1"/><col width="100" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>SNPs</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>dbSNP ID</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Forward primer</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Reverse primer</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Tm (&#x000b0;C)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Restriction enzyme</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02212;169C/T (fcrl3_3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7528684">rs7528684</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAAAATAATACA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGCTTTAAAA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">BsmFI<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AATGTACAGATTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AACGGTGGTAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02212;110A/G (fcrl3_4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11264799">rs11264799</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTCAATCCCGGT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTCATAACAAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">PleI<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGTGATACA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTATGTGAGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">+358C/G (fcrl3_5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=945635">rs945635</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TTATAGCCCATCTA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCGGGATTGAGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">HaeIII<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTCACTCAGGATCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TACAAACAGCATTT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">+1381A/G (fcrl3_6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761959">rs3761959</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCCGACTTTTTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGATAGCAGCACTA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">MspI<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">GTCTCTAGGTTTT</td><td valign="top" align="left" rowspan="1" colspan="1">GCTTGGACATTCA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>PCR was performed in 15 &#x003bc;l volumes containing 7.5 &#x003bc;l Premix Taq (Ex Taq Version; TaKaRa Biotechnology Co. Ltd., Dalian, China), 0.5 &#x003bc;l primers (10 &#x003bc;mol/l), and 0.1 &#x003bc;g of genomic DNA. The PCR products were then digested by the proper restriction enzymes, separated by electrophoresis on 2%&#x02212;3% agarose gel, and stained with GoldView&#x02122; (SBS Genetech, Beijing, China). The images were recorded digitally. Approximately 20% of the PCR samples were directly sequenced to confirm the PCR-RFLP results (Invitrogen Biotechnology Co., Guangzhou, China). <italic>HLA-DR4</italic> genotyping was performed using the PCR sequence specific primers (SSP) method [<xref ref-type="bibr" rid="r24">24</xref>]. <italic>HLA-DRw53</italic> typing was performed as described previously [<xref ref-type="bibr" rid="r25">25</xref>].</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed with the SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL). The Hardy&#x02013;Weinberg equilibrium (HWE) was tested by the &#x003c7;<sup>2</sup> test. We evaluated the frequency of alleles and genotypes in this study using the &#x003c7;<sup>2</sup> test or Fisher&#x02019;s exact test and accounting for multiple testing. The haplotype frequency and linkage disequilibrium (LD) of the SNPs were estimated with the <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview/">Haploview</ext-link> 3.32 program [<xref ref-type="bibr" rid="r26">26</xref>,<xref ref-type="bibr" rid="r27">27</xref>]. A haplotype frequency less than 0.03 was not analyzed. All the data were corrected by Bonferroni correction.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The test subjects consisted of 230 VKH patients (aged 33.4&#x000b1;12.6 years) and 301 healthy controls (aged 35.3&#x000b1;11.9 years). Of the 230 patients, 128 (55.7%) were men and 102 (44.3%) were women. No statistical difference was observed between patients and controls in the distribution of age and gender (p=0.43, p=0.82, respectively). All the cases and controls were in Hardy&#x02013;Weinberg equilibrium (p&#x0003e;0.05). Therefore, we did the following analysis.</p><p>Four SNPs (&#x02212;169C/T, &#x02212;110A/G, +358C/G, and +1381A/G) in <italic>FCRL3</italic> were determined in all patients and controls. The results showed that a significantly higher frequency of the G allele at the &#x02212;110 site of <italic>FCRL3</italic> was observed in VKH patients than in controls (p=0.0129), but this significance was lost after the Bonferroni correction (corrected p [Pc]=0.1032; <xref ref-type="table" rid="t3">Table 3</xref>). No significant difference was observed in the distribution of other tested alleles or genotypes between VKH patients and controls. The frequency of haplotype CACG was signficantly lower in VKH patients (0.3%) than in controls(3.0%; p=0.0018,Pc=0.0288, &#x003c7;<sup>2</sup>=9.77; <xref ref-type="table" rid="t4">Table 4</xref>).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Frequency of different alleles and genotypes in four <italic>FCRL3</italic> SNPs in VKH patients and controls.</title></caption><table frame="hsides" rules="groups"><col width="67" span="1"/><col width="112" span="1"/><col width="117" span="1"/><col width="50" span="1"/><col width="54" span="1"/><col width="36" span="1"/><col width="129" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>SNPs</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Patients n=230 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls n=301 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>&#x003c7;<sup>2</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Pc</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></th></tr></thead><tbody><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>&#x02212;169C/T</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">81 (35.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">87 (28.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.7365<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0936<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">82 (35.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">135 (44.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.7365<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0936<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (29.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79 (26.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.7365<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0936<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">244 (53.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">309 (51.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.3071<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5794<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.071 (0.840-1.366)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">216 (47.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">293 (48.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.3071<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5794<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>&#x02212;110A/G</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (7.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">46 (15.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.738<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0127<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">81 (35.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">98 (32.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.738<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0127<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">131 (57.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">155 (51.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.738<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0127<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">113 (24.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">190 (31.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6.174<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0129<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.707 (0.538-0.930)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">343 (75.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">408 (68.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6.174<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0129<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>+358C/G</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">75 (32.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">100 (33.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.619<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><underline>0.734</underline><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">104 (45.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">141 (47.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.619<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><underline>0.734</underline><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">51 (22.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58 (19.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.619<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><underline>0.734</underline><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">254 (55.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">341 (55.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.345<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><underline>0.557</underline><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.929 (0.727-1.187)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">206(44.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">257 (43.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.345<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><underline>0.557</underline><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>+1381A/G</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">135 (64.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">150 (58.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.279<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.016<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">72 (34.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">91 (35.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.279<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.016<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15 (5.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.279<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.016<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">199 (43.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">260 (56.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.356<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5078<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02014;<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G</td><td valign="top" align="center" rowspan="1" colspan="1">256 (42.7)</td><td valign="top" align="center" rowspan="1" colspan="1">344 (57.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1.356</td><td valign="top" align="center" rowspan="1" colspan="1">0.5078</td><td valign="top" align="center" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Pc: Corrected p value; NS: Not significant; OR: odds ratios.</p></table-wrap-foot></table-wrap><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Frequencies of <italic>FCRL3</italic> haplotypes in VKH patients and controls.</title></caption><table frame="hsides" rules="groups"><col width="72" span="1"/><col width="117" span="1"/><col width="126" span="1"/><col width="36" span="1"/><col width="63" span="1"/><col width="45" span="1"/><col width="82" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Haplotypes</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>VKH 2n=456 (%)*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls 2n=594 (%)*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>&#x003c7;<sup>2</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Fisher&#x02019;s p</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Pc</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C A C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.57 (0.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17.95 (3.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.77<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0018<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0288<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.1 (0.02-0.59)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C A G A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78.4 (17.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">112.0 (18.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.21<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.6454<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.9 (0.67-1.28)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C G C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">47.5 (10.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">38.1 (6.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6.34<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0118<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (1.13-2.76)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C G G A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">91.1 (20.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116.9 (19.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.14<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.7137<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.1 (0.78-1.45)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">T A C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14.7 (3.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">44.4 (7.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0044<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0704<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.4 (0.23-0.78)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">T G C G</td><td valign="top" align="center" rowspan="1" colspan="1">175.4 (38.5)</td><td valign="top" align="center" rowspan="1" colspan="1">219.8 (37.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.81</td><td valign="top" align="center" rowspan="1" colspan="1">0.3698</td><td valign="top" align="center" rowspan="1" colspan="1">NS</td><td valign="top" align="center" rowspan="1" colspan="1">1.1 (0.87-1.46)</td></tr></tbody></table><table-wrap-foot><p>The asterisk indicates that the frequency is less than 3% in both VKH cases and control.</p></table-wrap-foot></table-wrap><p>We further analyzed the relationship between these SNPs and various extraocular clinical findings including neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo. The detailed clinical findings of the enrolled VKH patients are shown in <xref ref-type="table" rid="t1">Table 1</xref>. No significant difference was noted between any clinical parameter stated above and the investigated SNPs.</p><p><italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> were also determined in VKH patients and controls using the PCR-SSP and PCR method [<xref ref-type="bibr" rid="r24">24</xref>,<xref ref-type="bibr" rid="r25">25</xref>]. The results showed that the frequencies of both <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> were significantly higher in VKH patients than in healthy controls (77.4% versus 19.6%, p=7.34&#x000d7;10<sup>&#x02212;16</sup> and 87.8% versus 64.1%, p=5.59&#x000d7;10<sup>&#x02212;10</sup>, respectively). Stratification analysis was then performed according to the status of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic>. A significant difference was found in the frequency of haplotype CGGG between <italic>HLA-DR4</italic> negative patients and <italic>HLA-DR4</italic> negative controls (5.8% versus 0%, p=9.94&#x000d7;10<sup>&#x02212;8</sup>, Pc=1.59&#x000d7;10<sup>&#x02212;6</sup>; <xref ref-type="table" rid="t5">Table 5</xref>). The results did not show any association of allele and genotype frequencies of the four SNPs between VKH patients and normal controls following these stratifications.</p><table-wrap id="t5" position="float"><label>Table 5</label><caption><title>Frequencies of <italic>FCRL3</italic> haplotypes in <italic>HLA-DR4</italic> negative VKH patients and <italic>HLA-DR4</italic> negative controls.</title></caption><table frame="hsides" rules="groups"><col width="69" span="1"/><col width="110" span="1"/><col width="135" span="1"/><col width="43" span="1"/><col width="63" span="1"/><col width="59" span="1"/><col width="103" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Haplotypes</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>VKH 2n=100 (%)*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls 2n=478 (%)*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>&#x003c7;<sup>2</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Fisher&#x02019;s p</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Pc</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C A C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.45 (2.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16.79 (3.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.26<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.6102<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.7 (0.18-0.74)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C A G A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16.59 (16.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">86.29 (18.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.074<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.785502<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.9 (0.52-1.65)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C G C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6.76 (6.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27.20 (5.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.21<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.646662<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.2 (0.51-2.94)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C G G A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23.80 (23.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">94.85 (19.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.987<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.320533<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.3 (0.77-2.19)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">T A C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.39 (2.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35.27 (7.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.274<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.070433<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.3 (0.08-1.18)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">T G C G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33.09 (31)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">182.16 (38.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.704<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.401591<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.8 (0.51-1.31)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C G G G</td><td valign="top" align="center" rowspan="1" colspan="1">5.78 (5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.000)</td><td valign="top" align="center" rowspan="1" colspan="1">28.469</td><td valign="top" align="center" rowspan="1" colspan="1">9.94e-08</td><td valign="top" align="center" rowspan="1" colspan="1">5.19e-006</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>The asterisk indicates that the frequency was less than 3% in both VKH case and control.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>We analyzed the association of the aforementioned four SNPs and haplotypes of <italic>FCRL3</italic> in the susceptibility to VKH syndrome in a Chinese population. The results showed that the frequency of haplotype CACG was significantly lower in VKH patients and that the frequency of haplotype CGGG was significantly higher in <italic>HLA-DR4</italic> negative VKH patients. The results also confirmed the association of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> with VKH syndrome as expected. Furthermore, previous studies showed strong associations between <italic>FCRL3</italic> polymorphisms and RA in Asian groups but hardly in Caucasians [<xref ref-type="bibr" rid="r16">16</xref>] except a study in Spain [<xref ref-type="bibr" rid="r28">28</xref>], which showed that <italic>FCRL3</italic> polymorphisms were associated with RA after stratification by nuclear factor kappa B1 (NF-&#x003ba;B1). VKH syndrome is quite common in both Asian and Spanish populations. The association between <italic>FCRL3</italic> and VKH may be of importance in Chinese VKH patients and Hispanic VKH patients.</p><p>The test patients were strictly enrolled as VKH syndrome patients according to the revised criteria [<xref ref-type="bibr" rid="r22">22</xref>]. As ethnic confounding could influence the results, we selected only Chinese Han descendents as the test subjects. Moreover, the healthy controls in this study were all limited to persons who came from the same places as the patients, which avoided a geographic bias.</p><p>As a novel immunoregulatory gene, <italic>FCRL3</italic> has been reported to be positively associated with various autoimmune diseases in different ethnic populations [<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r19">19</xref>,<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r29">29</xref>,<xref ref-type="bibr" rid="r30">30</xref>], though certain results were conflicting [<xref ref-type="bibr" rid="r28">28</xref>,<xref ref-type="bibr" rid="r31">31</xref>]. A study by Kochi et al. [<xref ref-type="bibr" rid="r17">17</xref>] in Japan found that the four SNPs of <italic>FCRL3</italic> (&#x02212;169C/T, &#x02212;110A/G, +358C/G, and +1381A/G) were associated with RA and that SNP &#x02212;169C/T was associated with AITD and SLE. Furthermore, &#x02212;169C/T SNP has been shown to influence the level of <italic>FCRL3</italic> expression on B cells by altering the binding affinity of NF-&#x003ba;B, which appears to play a major role in the inflammatory response according to recent studies [<xref ref-type="bibr" rid="r32">32</xref>]. Therefore, we speculated that polymorphisms within <italic>FCRL3</italic> could also be related to VKH syndrome.</p><p>Although no significant differences were found in the frequencies of the four investigated SNPs of <italic>FCRL3</italic> between VKH patients and normal controls, an increase trend was observed in the frequency of the &#x02212;110G allele in VKH patients. This result is similar to the study we recently reported in Behcet&#x02019;s disease in which only the <italic>FCRL3</italic> &#x02212;110G allele was significantly higher in BD patients and no differences were observed in the remaining three tested SNPs [<xref ref-type="bibr" rid="r18">18</xref>]. The polymorphisms of <italic>FCRL3</italic> were reported to be associated with RA in Japan [<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r30">30</xref>] and MS in Spain [<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>], but the associations could not be replicated completely in other autoimmune diseases [<xref ref-type="bibr" rid="r23">23</xref>,<xref ref-type="bibr" rid="r33">33</xref>]. In the study of Graves&#x02019; disease [<xref ref-type="bibr" rid="r19">19</xref>], three of the four SNPs (except &#x02212;110A/G SNP) were associated with this autoimmune thyroid disease. A study by Japanese investigators [<xref ref-type="bibr" rid="r34">34</xref>] also showed that only &#x02212;110A/G SNP was associated with autoimmune pancreatitis, but contrary to our result, the frequency of &#x02212;110G allele was decreased in these patients. Similar negative results were obtained for the same four SNPs of <italic>FCRL3</italic> in other studies concerning type 1 autoimmune hepatitis in the Japanese [<xref ref-type="bibr" rid="r35">35</xref>] and SLE in the Chinese population [<xref ref-type="bibr" rid="r36">36</xref>]. These observations demonstrated that the relationship between polymorphisms of <italic>FCRL3</italic> and autoimmune diseases is more complex than we thought, especially in some multiple autoimmune disorders.</p><p>The further haplotype analysis showed that the frequency of haplotype CACG was significantly lower in VKH patients. This suggests that the haplotype CACG might be a protective haplotype for VKH syndrome. However, the frequency of this haplotype in patients and controls is very low (0.3% versus 3%), making it hard to make any firm conclusion on this significance. The present results were different from those found in BD [<xref ref-type="bibr" rid="r18">18</xref>] and SLE [<xref ref-type="bibr" rid="r37">37</xref>]. The study of BD in our laboratory found that haplotype CGCG and TACG were both associated with BD in which the first one was found to be significantly higher whereas the latter was significantly lower in BD patients as compared with healthy controls. While in the study of SLE in Spanish individuals, only three alleles were examined and the frequency of haplotype CGA was found to be significantly higher in SLE patients than in controls.</p><p>VKH occurs most commonly in pigmented individuals and not in whites, but interestingly, the disease is rare in Africans [<xref ref-type="bibr" rid="r7">7</xref>]. It seems that the genetic background in these individuals rather than the amount of pigment is the predisposing factor to VKH syndrome. Various studies have reported that <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> were significantly associated with VKH syndrome [<xref ref-type="bibr" rid="r8">8</xref>-<xref ref-type="bibr" rid="r10">10</xref>]. We therefore analyzed the association of the four SNPs with VKH syndrome based on the <italic>HLA-DR4</italic> and <italic>HLA- DRw53</italic> stratification. We found that the association of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> with VKH syndrome was extremely strong, which is consistent with earlier studies from China [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r38">38</xref>], Japan [<xref ref-type="bibr" rid="r10">10</xref>], Korea [<xref ref-type="bibr" rid="r39">39</xref>], and Hispanic patients living in California [<xref ref-type="bibr" rid="r40">40</xref>]. However, stratification analysis according to the status of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> still showed that none of the four SNPs was associated to VKH syndrome. However, the frequency of haplotype CGGG was significantly higher in <italic>HLA-DR4</italic> negative patients than in <italic>HLA-DR4</italic> negative controls. Haplotype CGGG is probably a risk haplotype predisposing to VKH syndrome in <italic>HLA-DR4</italic> negative subgroups. The samples become small after stratification, consisting of 52 <italic>HLA-DR4</italic> negative VKH patients and 242 <italic>HLA-DR4</italic> negative normal controls. The influence of insufficient sample size can not be excluded yet. Various studies showed that VKH shared epitopes with other autoimmune disease-associated HLA alleles [<xref ref-type="bibr" rid="r41">41</xref>-<xref ref-type="bibr" rid="r43">43</xref>]. <italic>HLA-DQB1</italic>, -<italic>DR1</italic>, and -<italic>DR4</italic> all were susceptible genes for VKH syndrome [<xref ref-type="bibr" rid="r44">44</xref>], and importantly, these HLA antigens were also associated with the susceptibility to other autoimmune diseases including type 1 diabetes [<xref ref-type="bibr" rid="r45">45</xref>]and Graves' disease [<xref ref-type="bibr" rid="r46">46</xref>].</p><p>Systemic disease is a prominent feature of VKH syndrome. There is a large variation in systemic clinical manifestations in Chinese VKH patients [<xref ref-type="bibr" rid="r4">4</xref>]. Stratification analysis was therefore performed to investigate the association between the polymorphisms of <italic>FCRL3</italic> and clinical manifestations. The results showed that none of these clinical findings, which included neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo, was significantly associated with the four SNPs. Similarly, no association was found after gender and age stratification.</p><p>In conclusion, no significant correlation could be observed between the <italic>FCRL3</italic> polymorphisms and VKH syndrome in the Chinese population. Haplotype CACG might be a protective haplotype for VKH syndrome. Haplotype CGGG is probably a risk haplotype in <italic>HLA-DR4</italic> negative individuals. Similar to previous studies, we found strong associations of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> with VKH syndrome. Further studies of these SNPs and including other variants in the <italic>FCRL3</italic> region, using larger (multi-center) patient numbers, and including various autoimmune diseases should be performed in the future.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the Key Project of Natural Science Foundation (30630064), National Supporting Project of P.R. China (2007BAI18B10), Clinical Key Project of Ministry of Health of P.R China, and Key Project of Chongqing Health Bureau and National Basic Research Program of China (2007CB512200).</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Klooster</surname><given-names>J</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China.</article-title><source>Curr Eye Res</source><year>2005</year><volume>30</volume><fpage>943</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16282128</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moorthy</surname><given-names>RS</given-names></name><name><surname>Inomata</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Vogt-Koyanagi-Harada syndrome.</article-title><source>Surv Ophthalmol</source><year>1995</year><volume>39</volume><fpage>265</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">7725227</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>DJ</given-names></name><name><surname>Cano</surname><given-names>MR</given-names></name><name><surname>Green</surname><given-names>RL</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Echographic features of the Vogt-Koyanagi-Harada syndrome.</article-title><source>Arch Ophthalmol</source><year>1990</year><volume>108</volume><fpage>1421</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2222275</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>606</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17123618</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>SJ</given-names></name></person-group><article-title>Update on uveomeningoencephalitides.</article-title><source>Curr Opin Neurol</source><year>2005</year><volume>18</volume><fpage>323</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15891420</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaki</surname><given-names>K</given-names></name><name><surname>Gocho</surname><given-names>K</given-names></name><name><surname>Sakuragi</surname><given-names>S</given-names></name></person-group><article-title>Pathogenesis of Vogt-Koyanagi-Harada disease.</article-title><source>Int Ophthalmol Clin</source><year>2002</year><volume>42</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12189608</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreoli</surname><given-names>CM</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name></person-group><article-title>Vogt-Koyanagi-Harada disease.</article-title><source>Int Ophthalmol Clin</source><year>2006</year><volume>46</volume><fpage>111</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16770158</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Abrahams</surname><given-names>IW</given-names></name></person-group><article-title>Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population.</article-title><source>Arch Ophthalmol</source><year>1991</year><volume>109</volume><fpage>368</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2003797</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>XM</given-names></name><name><surname>Hu</surname><given-names>TS</given-names></name></person-group><article-title>Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome.</article-title><source>Am J Ophthalmol</source><year>1992</year><volume>113</volume><fpage>567</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">1575232</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>SM</given-names></name><name><surname>Numaga</surname><given-names>J</given-names></name><name><surname>Fujino</surname><given-names>Y</given-names></name><name><surname>Hirata</surname><given-names>R</given-names></name><name><surname>Matsuki</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name></person-group><article-title>HLA class II genes in Vogt-Koyanagi-Harada disease.</article-title><source>Invest Ophthalmol Vis Sci</source><year>1994</year><volume>35</volume><fpage>3890</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7928186</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Small ubiquitin-like modifier 4 (SUMO4) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>2597</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">19122825</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome.</article-title><source>Clin Immunol</source><year>2008</year><volume>127</volume><fpage>43</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18282809</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Kubagawa</surname><given-names>H</given-names></name><name><surname>Cooper</surname><given-names>MD</given-names></name></person-group><article-title>Identification of a family of Fc receptor homologs with preferential B cell expression.</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>9772</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11493702</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>RS</given-names></name><name><surname>Dennis</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Odom</surname><given-names>MR</given-names></name><name><surname>Gibson</surname><given-names>AW</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name><name><surname>Burrows</surname><given-names>PD</given-names></name><name><surname>Cooper</surname><given-names>MD</given-names></name></person-group><article-title>Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family.</article-title><source>Immunol Rev</source><year>2002</year><volume>190</volume><fpage>123</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12493010</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>RS</given-names></name></person-group><article-title>Fc receptor-like molecules.</article-title><source>Annu Rev Immunol</source><year>2007</year><volume>25</volume><fpage>525</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">17201682</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chistiakov</surname><given-names>DA</given-names></name><name><surname>Chistiakov</surname><given-names>AP</given-names></name></person-group><article-title>Is FCRL3 a new general autoimmunity gene?</article-title><source>Hum Immunol</source><year>2007</year><volume>68</volume><fpage>375</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">17462505</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kochi</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Shirasawa</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Bae</surname><given-names>SC</given-names></name><name><surname>Tokuhiro</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name><name><surname>Kaufman</surname><given-names>KM</given-names></name><name><surname>Kang</surname><given-names>CP</given-names></name><name><surname>Kang</surname><given-names>C</given-names></name><name><surname>Otsubo</surname><given-names>S</given-names></name><name><surname>Yumura</surname><given-names>W</given-names></name><name><surname>Mimori</surname><given-names>A</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Sasazuki</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name></person-group><article-title>A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities.</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>478</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15838509</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name></person-group><article-title>Association between polymorphisms of FCRL3, a non-HLA gene, and Behcet's disease in a Chinese population with ophthalmic manifestations.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>2136</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">19050767</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>MJ</given-names></name><name><surname>Heward</surname><given-names>JM</given-names></name><name><surname>Carr-Smith</surname><given-names>J</given-names></name><name><surname>Foxall</surname><given-names>H</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name><name><surname>Gough</surname><given-names>SC</given-names></name></person-group><article-title>Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease.</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>1056</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16384851</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matesanz</surname><given-names>F</given-names></name><name><surname>Fernandez</surname><given-names>O</given-names></name><name><surname>Milne</surname><given-names>RL</given-names></name><name><surname>Fedetz</surname><given-names>M</given-names></name><name><surname>Leyva</surname><given-names>L</given-names></name><name><surname>Guerrero</surname><given-names>M</given-names></name><name><surname>Delgado</surname><given-names>C</given-names></name><name><surname>Lucas</surname><given-names>M</given-names></name><name><surname>Izquierdo</surname><given-names>G</given-names></name><name><surname>Alcina</surname><given-names>A</given-names></name></person-group><article-title>The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis.</article-title><source>J Neuroimmunol</source><year>2008</year><volume>195</volume><fpage>146</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">18313765</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Mas</surname><given-names>A</given-names></name><name><surname>de Las Heras</surname><given-names>V</given-names></name><name><surname>Bartolome</surname><given-names>M</given-names></name><name><surname>Arroyo</surname><given-names>R</given-names></name><name><surname>Fernandez-Arquero</surname><given-names>M</given-names></name><name><surname>de la Concha</surname><given-names>EG</given-names></name><name><surname>Urcelay</surname><given-names>E</given-names></name></person-group><article-title>FcRL3 and multiple sclerosis pathogenesis: role in autoimmunity?</article-title><source>J Neuroimmunol</source><year>2007</year><volume>189</volume><fpage>132</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17617473</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>RW</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Tabbara</surname><given-names>KF</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Arellanes-Garcia</surname><given-names>L</given-names></name><name><surname>Pivetti-Pezzi</surname><given-names>P</given-names></name><name><surname>Tessler</surname><given-names>HH</given-names></name><name><surname>Usui</surname><given-names>M</given-names></name></person-group><article-title>Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.</article-title><source>Am J Ophthalmol</source><year>2001</year><volume>131</volume><fpage>647</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11336942</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>CJ</given-names></name><name><surname>Kelly</surname><given-names>H</given-names></name><name><surname>Eden</surname><given-names>JA</given-names></name><name><surname>Merriman</surname><given-names>ME</given-names></name><name><surname>Pearce</surname><given-names>SH</given-names></name><name><surname>Merriman</surname><given-names>TR</given-names></name></person-group><article-title>Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association.</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>1106</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">17200162</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zetterquist</surname><given-names>H</given-names></name><name><surname>Olerup</surname><given-names>O</given-names></name></person-group><article-title>Identification of the HLA-DRB1*04, -DRB1*07, and -DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours.</article-title><source>Hum Immunol</source><year>1992</year><volume>34</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">1356957</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname><given-names>L</given-names></name><name><surname>Sorrentino</surname><given-names>R</given-names></name><name><surname>Saltini</surname><given-names>C</given-names></name></person-group><article-title>HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.</article-title><source>Science</source><year>1993</year><volume>262</volume><fpage>242</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8105536</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>ZS</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name></person-group><article-title>Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms.</article-title><source>Am J Hum Genet</source><year>2002</year><volume>71</volume><fpage>1242</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12452179</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Valdivia</surname><given-names>A</given-names></name><name><surname>Orozco</surname><given-names>G</given-names></name><name><surname>Lopez-Nevot</surname><given-names>MA</given-names></name><name><surname>Pascual-Salcedo</surname><given-names>D</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Fernandez-Gutierrez</surname><given-names>B</given-names></name><name><surname>de la Concha</surname><given-names>EG</given-names></name><name><surname>Garcia-Sanchez</surname><given-names>A</given-names></name><name><surname>Koeleman</surname><given-names>BP</given-names></name><name><surname>Urcelay</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name></person-group><article-title>Epistatic interaction between FCRL3 and NFkappaB1 genes in Spanish patients with rheumatoid arthritis.</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>1188</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16476711</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thabet</surname><given-names>MM</given-names></name><name><surname>Wesoly</surname><given-names>J</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name></person-group><article-title>FCRL3 promoter 169 CC homozygosity is associated with susceptibility to rheumatoid arthritis in Dutch Caucasians.</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>803</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17179172</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikari</surname><given-names>K</given-names></name><name><surname>Momohara</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Tomatsu</surname><given-names>T</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name></person-group><article-title>Supportive evidence for a genetic association of the FCRL3 promoter polymorphism with rheumatoid arthritis.</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>671</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">16176992</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Begovich</surname><given-names>AB</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Schrodi</surname><given-names>SJ</given-names></name></person-group><article-title>Meta-analysis evidence of a differential risk of the FCRL3 &#x02212;169T&#x02192;C polymorphism in white and East Asian rheumatoid arthritis patients.</article-title><source>Arthritis Rheum</source><year>2007</year><volume>56</volume><fpage>3168</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17763442</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Andersson</surname><given-names>R</given-names></name></person-group><article-title>NF-kappaB activation and inhibition: a review.</article-title><source>Shock</source><year>2002</year><volume>18</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">12166787</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Nunez</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>MC</given-names></name><name><surname>Mendoza</surname><given-names>JL</given-names></name><name><surname>Taxonera</surname><given-names>C</given-names></name><name><surname>Diaz-Rubio</surname><given-names>M</given-names></name><name><surname>de la Concha</surname><given-names>EG</given-names></name><name><surname>Urcelay</surname><given-names>E</given-names></name></person-group><article-title>Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD.</article-title><source>Tissue Antigens</source><year>2007</year><volume>69</volume><fpage>313</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17389014</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umemura</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Hamano</surname><given-names>H</given-names></name><name><surname>Katsuyama</surname><given-names>Y</given-names></name><name><surname>Kiyosawa</surname><given-names>K</given-names></name><name><surname>Kawa</surname><given-names>S</given-names></name></person-group><article-title>Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients.</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>1367</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16905709</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umemura</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Yoshizawa</surname><given-names>K</given-names></name><name><surname>Katsuyama</surname><given-names>Y</given-names></name><name><surname>Ichijo</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>E</given-names></name><name><surname>Kawa</surname><given-names>S</given-names></name><name><surname>Kiyosawa</surname><given-names>K</given-names></name></person-group><article-title>Lack of association between FCRL3 and FcgammaRII polymorphisms in Japanese type 1 autoimmune hepatitis.</article-title><source>Clin Immunol</source><year>2007</year><volume>122</volume><fpage>338</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17020818</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Hao</surname><given-names>F</given-names></name></person-group><article-title>Lack of association between Fc receptor-like 3 gene polymorphisms and systemic lupus erythematosus in Chinese population.</article-title><source>J Dermatol Sci</source><year>2008</year><volume>52</volume><fpage>118</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18556175</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Callejas</surname><given-names>JL</given-names></name><name><surname>Sabio</surname><given-names>JM</given-names></name><name><surname>de Haro</surname><given-names>M</given-names></name><name><surname>Camps</surname><given-names>M</given-names></name><name><surname>de Ramon</surname><given-names>E</given-names></name><name><surname>Garcia-Hernandez</surname><given-names>FJ</given-names></name><name><surname>Koeleman</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Gonzalez-Escribano</surname><given-names>MF</given-names></name></person-group><article-title>Polymorphisms of the FCRL3 gene in a Spanish population of systemic lupus erythematosus patients.</article-title><source>Rheumatology (Oxford)</source><year>2006</year><volume>45</volume><fpage>1044</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16717063</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>X</given-names></name></person-group><article-title>The association of HLA-DR4 gene subtypes with Vogt-Koyanagi-Harada syndrome.</article-title><source>Zhonghua Yan Ke Za Zhi</source><year>1997</year><volume>33</volume><fpage>268</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10451958</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Seong</surname><given-names>MC</given-names></name><name><surname>Kwak</surname><given-names>NH</given-names></name><name><surname>Yoo</surname><given-names>JS</given-names></name><name><surname>Huh</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>TG</given-names></name><name><surname>Han</surname><given-names>H</given-names></name></person-group><article-title>Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans.</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>173</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10682969</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weisz</surname><given-names>JM</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Roer</surname><given-names>LN</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Yuge</surname><given-names>AJ</given-names></name><name><surname>Moorthy</surname><given-names>RS</given-names></name><name><surname>Forster</surname><given-names>DJ</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Terasaki</surname><given-names>PI</given-names></name></person-group><article-title>Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California.</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>1012</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9121744</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Atoh</surname><given-names>M</given-names></name><name><surname>Yagita</surname><given-names>A</given-names></name><name><surname>Konoeda</surname><given-names>Y</given-names></name><name><surname>Inoko</surname><given-names>H</given-names></name><name><surname>Ando</surname><given-names>A</given-names></name><name><surname>Sekiguchi</surname><given-names>S</given-names></name></person-group><article-title>Crohn's disease in the Japanese is associated with the HLA-DRw53.</article-title><source>Exp Clin Immunogenet</source><year>1990</year><volume>7</volume><fpage>101</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2322470</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garavito</surname><given-names>G</given-names></name><name><surname>Malagon</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>LA</given-names></name><name><surname>De La Cruz</surname><given-names>OF</given-names></name><name><surname>Uribe</surname><given-names>O</given-names></name><name><surname>Navarro</surname><given-names>E</given-names></name><name><surname>Iglesias</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>P</given-names></name><name><surname>Jaraquemada</surname><given-names>D</given-names></name><name><surname>Egea</surname><given-names>E</given-names></name></person-group><article-title>Polymorphism of human HLA-DRB1 leukocyte antigen alleles and its association to juvenile rheumatoid arthritis in a sample of Colombian mestizo children.</article-title><source>Biomedica</source><year>2003</year><volume>23</volume><fpage>254</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14582328</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>I</given-names></name><name><surname>Collado</surname><given-names>J</given-names></name><name><surname>Daura</surname><given-names>X</given-names></name><name><surname>Colome</surname><given-names>N</given-names></name><name><surname>Rodriguez-Garcia</surname><given-names>M</given-names></name><name><surname>Gallart</surname><given-names>T</given-names></name><name><surname>Canals</surname><given-names>F</given-names></name><name><surname>Jaraquemada</surname><given-names>D</given-names></name></person-group><article-title>The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401).</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>1630</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18512783</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levinson</surname><given-names>RD</given-names></name><name><surname>See</surname><given-names>RF</given-names></name><name><surname>Rajalingam</surname><given-names>R</given-names></name><name><surname>Reed</surname><given-names>EF</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name></person-group><article-title>HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt-Koyanagi-Harada's disease in Southern California.</article-title><source>Hum Immunol</source><year>2004</year><volume>65</volume><fpage>1477</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15603876</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Awata</surname><given-names>T</given-names></name><name><surname>Kanazawa</surname><given-names>Y</given-names></name></person-group><article-title>Genetic markers for insulin-dependent diabetes mellitus in Japanese.</article-title><source>Diabetes Res Clin Pract</source><year>1994</year><volume>24</volume><issue>Suppl</issue><fpage>S83</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7859639</pub-id></citation></ref><ref id="r46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Asaba</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Takao</surname><given-names>T</given-names></name><name><surname>Iwasaki</surname><given-names>Y</given-names></name><name><surname>Kumon</surname><given-names>Y</given-names></name><name><surname>Suehiro</surname><given-names>T</given-names></name><name><surname>Tanimoto</surname><given-names>N</given-names></name><name><surname>Mizobuchi</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population.</article-title><source>Horm Res</source><year>2005</year><volume>64</volume><fpage>253</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16254435</pub-id></citation></ref></ref-list></back></article> 